The current stock price of SENS is 6.05 USD. In the past month the price increased by 0.5%. In the past year, price decreased by -48.92%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.01 | 217.03B | ||
| ISRG | INTUITIVE SURGICAL INC | 67.03 | 204.60B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.59 | 142.51B | ||
| SYK | STRYKER CORP | 26.94 | 135.66B | ||
| BDX | BECTON DICKINSON AND CO | 13.6 | 55.98B | ||
| IDXX | IDEXX LABORATORIES INC | 54.57 | 54.95B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.58 | 50.07B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.17 | 37.99B | ||
| RMD | RESMED INC | 24.69 | 35.68B | ||
| DXCM | DEXCOM INC | 36.25 | 26.30B | ||
| PODD | INSULET CORP | 63.2 | 20.32B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.15 | 17.88B |
Senseonics Holdings Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Germantown, Maryland and currently employs 117 full-time employees. The company went IPO on 2015-03-04. Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems Eversense 365 and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Its CGM systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and 180 days for Eversense E3 in persons with diabetes age 18 and older. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device.
SENSEONICS HOLDINGS INC
20451 Seneca Meadows Pkwy
Germantown MARYLAND 20876 US
CEO: Timothy T. Goodnow
Employees: 117
Phone: 13015157260
Senseonics Holdings Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Germantown, Maryland and currently employs 117 full-time employees. The company went IPO on 2015-03-04. Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems Eversense 365 and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Its CGM systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and 180 days for Eversense E3 in persons with diabetes age 18 and older. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device.
The current stock price of SENS is 6.05 USD. The price decreased by -2.1% in the last trading session.
SENS does not pay a dividend.
SENS has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
SENSEONICS HOLDINGS INC (SENS) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
SENSEONICS HOLDINGS INC (SENS) will report earnings on 2026-03-02, after the market close.
The outstanding short interest for SENSEONICS HOLDINGS INC (SENS) is 9.94% of its float.
ChartMill assigns a technical rating of 1 / 10 to SENS. When comparing the yearly performance of all stocks, SENS is a bad performer in the overall market: 92.54% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to SENS. While SENS seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months SENS reported a non-GAAP Earnings per Share(EPS) of -1.63. The EPS increased by 37.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.39% | ||
| ROE | -72.01% | ||
| Debt/Equity | 0.37 |
For the next year, analysts expect an EPS growth of 36.15% and a revenue growth 59.44% for SENS